The long QT syndrome may occur due to genetic aberrations of cardiac transcellular ionic transporters, but also occurs secondary to a wide range of therapeutic and illicit drugs. This review will outline how the interaction of the blockade of the cardiac ion channels with drugs may lead to death from the long QT syndrome. Toxicology laboratories have a role, although somewhat limited, in supporting the investigation of sudden adult death and the contribution to the etiology of the long QT syndrome.
BehrE.R., CaseyA., SheppardM.Sudden arrhythmic death syndrome: a national survey of sudden unexplained cardiac death.Heart.2007 May; 93(5): 601–5.
2.
TanH.L., HofmanN., van LangenI.M.Sudden unexplained death: heritability and diagnostic yield of cardiological and genetic examination in surviving relatives.Circulation.2005 Jul 12; 112(2): 207–13.
3.
SelzerA., WrayH.W.Quinidine syncope. Paroxysmal ventricular fibrillation occurring during treatment of chronic atrial arrhythmias.Circulation.1964 Jul; 30: 17–26.
4.
DessertenneF.[Ventricular tachycardia with 2 variable opposing foci] [Article in French].Arch Mal Coeur Vaiss.1966 Feb; 59(2): 263–72.
5.
SandanagaT., SadanagaF., YaoH., FuiishimaM.An evaluation of ECG leads use to assess QT prolongation.Cardiology.2006; 105(3): 149–54.
6.
SurawiczB., KnilansT.Chou's Electrocardiography in Clinical Practice: Adult and Pediatric.3rd ed.Philadelphia: W.B. Saunders Company; 2001. 709 p.
7.
MorganrothJ., BrozovichF.V., McDonaldJ.T., JacobsR.A., Variability of the QT measurement in healthy men, with implications for selection of an abnormal QT value to predict drug toxicity and proarrhythmia.Am J Cardiol.1991 Apr 1; 67(8): 774–6.
8.
MolnarJ., ZhangF., WeissJ.Diurnal pattern of QTc interval: how long is prolonged? Possible relation to circadian triggers of cardiovascular events.J Am Coll Cardiol.1996 Jan; 27(1): 76–83.
9.
SanguinettiM.C., JurkiewiczN.K.Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents.J Gen Physiol.1990 Jul; 96(1): 195–215.
10.
SanguinettiM.C., JurkiewiczN.K.Delayed rectifier outward K+ current is composed of two currents in guinea pig atrial cells.Am J Physiol.1991 Feb; 260(2 Pt 2): H393–9.
11.
GintantG.A.Two components of delayed rectifier current in canine atrium and ventricle. Does IKs play a role in the reverse rate dependence of class III agents?Circ Res.1996 Jan; 78(1): 26–37.
12.
SanguinettiM.C., CurranM.E., ZouA.Coassembly of K(V)LQT1 and minK (IsK) proteins to form cardiac I(Ks) potassium channel.Nature.1996 Nov 7; 384(6604): 80–3.
13.
BarhaninJ., LesageF., GuillemareE.K(V)LQT1 and IsK (minK) proteins associate to form the I(Ks) cardiac potassium current.Nature.1996 Nov 7; 384(6604): 78–80.
14.
RodenD.M., ViswanathanP.C.Genetics of acquired long QT syndrome.J Clin Invest.2005 Aug; 115(8): 2025–32.
15.
CurranM.E., SplawskiI., TimothyK.W.A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome.Cell.1995 Mar 10; 80(5): 795–803.
16.
SanguinettiM.C., Tristani-FirouziM.hERG potassium channels and cardiac arrhythmia.Nature.2006 Mar 23; 440(7083): 463–9.
17.
FernandezD., GhantaA., KauffmanG.W., SanguinettiM.C.Physicochemical features of the HERG channel drug binding site.J Biol Chem.2004 Mar 12; 279(11): 10120–7.
18.
YapY.G., CammA.J.Drug induced QT prolongation and torsades de pointes.Heart.2003 Nov; 89(11): 1363–72.
19.
HinterseerM., ThomsenM.B., BeckmannB.M.Beat-to-beat variability of QT intervals is increased in patients with drug-induced long-QT syndrome: a case control pilot study.Eur Heart J.2008 Jan; 29(2): 185–90.
20.
RodenD.M., WoosleyR.L., PrimmR.K.Incidence and clinical feature of the quinidine-associated long QT syndrome: implications for patient care.Am Heart J.1986 Jun; 111(6): 1088–93.
21.
MakkarR.R., FrommB.S., SteinmanR.T.Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs.JAMA.1993 Dec 1; 270(21): 2590–7.
22.
RautaharjuP, ZhouS.H., WongS.Sex differences in the evolution of the electrocardiographic QT interval with age.Can J Cardiol.1992 Sep; 8(7): 690–5.
YangT., RodenD.M.Extracellular potassium modulation of drug block of IKr. Implications for torsade de pointes and reverse use-dependence.Circulation.1996 Feb 1; 93(3): 407–11.
25.
ChoyA.M., LangC.C., ChomskyD.M.Normalization of acquired QT prolongation in humans by intrave-nous potassium.Circulation.1997 Oct 7; 96(7): 2149–54.
26.
EtheridgeS.P., ComptonS.J., Tristani-FirouziM., MasonJ.W.A new oral therapy for long QT syndrome: long-term oral potassium improves repolarization in patients with HERG mutations.J Am Coll Cardiol.2003 Nov 19; 42(10): 1777–82.
27.
ChoyA.M., DarbarD., Dell'OrtoS., RodenD.M.Exaggerated QT prolongation after cardioversion of atrial fibrillation.J Am Coll Cardiol.1999 Aug; 34(2): 396–401.
28.
WyseK.R., YeV., CampbellT.J.Action potential prolongation exhibits simple dose-dependence for sotalol, but reverse dose-dependence for quinidine and diso-pyramide: implications for proarrhythmia due to triggered activity.J Cardiovasc Pharmacol.1993 Feb; 21(2): 316–22.
29.
DrouinE., LandeG., CharpentierF.Amiodarone reduces transmural heterogeneity of repolarization in the human heart.J Am Coll Cardiol.1998 Oct; 32(4): 1063–7.
30.
HohnloserS.H., KlingenhebenT., SinghB.N.Amioda-rone-associated proarrhythmic effects. A review with special reference to torsade de pointes tachycardia.Ann Intern Med.1994 Oct 1; 121(7): 529–35.
31.
VorperianV.R., HavighurstT.C., MillerS., JanuaryC.T.Adverse effects of low dose amiodarone: a meta-analysis.J Am Coll Cardiol.1997 Sep; 30(3): 791–8.
32.
LazzaraR.Antiarrhythmic drugs and torsade de pointes.Eur Heart J.1993 Nov; 14 Suppl H: 88–92.
33.
EllenbogenK.A., StamblerB.S., WoodM.A.Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study.J Am Coll Cardiol.1996 Jul; 28(1): 130–6.
34.
StamblerS., WoodM.A., EllenbogenK.A.Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators.Circulation.1996 Oct 1; 94(7): 1613–21.
35.
ZhangS., ZhouZ., GongQ.Mechanism of block and identification of the verapamil binding domain to HERG potassium channels.Circ Res.1999 May 14; 84(9): 989–98.
36.
ShimizuW., OheT., KuritaT.Effects of verapamil and propranolol on early after depolarizations and ventricular arrhythmias induced by epinephrine in congenital long QT syndrome.J Am Coll Cardiol.1995 Nov 1; 26(5): 1299–309.
37.
NapolitanoC., SchwartzP.J., BrownA.M.Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias.J Cardiovasc Electrophysiol.2000 Jun; 11(6): 691–6.
38.
YangP., KankiH., DroletB.Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes.Circulation.2002 Apr 23; 105(16): 1943–8.
39.
PrioriS.G., NapolitanoC., SchwartzP.J.Low penetrance in the long-QT syndrome: clinical impact.Circulation.1999 Feb 2; 99(4): 529–33.
40.
PrioriS.G., SchwartzP.J., NapolitanoC.Risk stratification in the long-QT syndrome.N Engl J Med.2003 May 8; 348(19): 1866–74.
41.
KannankerilP.J., RodenD.M., NorrisK.J.Genetic susceptibility to acquired long QT syndrome: pharmacologic challenge in first-degree relatives.Heart Rhythm.2005 Feb; 2(2): 134–40.
42.
PaulussenD.C., GilissenR.A., ArmstrongM.Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients.J Mol Med (Berl).2004 Mar; 82(3): 182–8.
43.
Mank-SeymourA.R., RichmondJ.L., WoodL.S.Association of torsades de pointes with novel and known single nucleotide polymorphisms in long QT syndrome genes.Am Heart J.2006 Dec; 152(6): 1116–22.
44.
FitzgeraldP.T., AckermanM.J.Drug-induced torsades de pointes: the evolving role of pharmacogenetics.Heart Rhythm.2005 Nov; 2(2 Suppl): S30–7.
45.
TesterD.J., AckermanM.J.Postmortem long QT syndrome genetic testing for sudden unexplained death in the young.J Am Coll Cardiol.2007 Jan 16; 49(2): 240–6.
46.
BehrE., WoodD.A., WrightM.Cardiological assessment of first-degree relatives in sudden arrhythmic death syndrome.Lancet.2003 Nov 1; 362(9394): 1457–9.
47.
TanH.L., HofmanN., van LangenI.M.Sudden unexplained death: heritability and diagnostic yield of cardiological and genetic examination in surviving relatives.Circulation.2005 Jul 12; 112(2): 207–13.
48.
TesterD.J., AckermanM.J.The molecular autopsy: should the evaluation continue after the funeral?Pediatr Cardiol.2012 Mar; 33(3): 461–70.
49.
RayW.A., ChungC.P., MurrayK.T.Atypical antipsychotic drugs and the risk of sudden cardiac death.N Engl J Med.2009 Jan 15; 360(3): 225–35.
PatilA.G., ReddyD., D'SouzaR., DamreA.Development and validation of RP-HPLC-fluorescence method for quantitative determination of quinidine, a probe substrate for P-glycoprotein inhibition assay using Caco-2 cell monolayer.Biomed Chromatogr.2010 Jun; 24(6): 620–5.
52.
LagerstrômP.O., PerssonB.A.Liquid chromatography in the monitoring of plasma levels of antiarrhythmic drugs.J Chromatogr.1978 Feb 11; 149: 331–40.
53.
FlanaganR.J., StoreyG.C., HoltD.W., FarmerP.B.Identification and measurement of desethylamiodarone in blood plasma specimens from amiodarone-treated patients.J Pharm Pharmacol.1982 Oct; 34(10): 638–43.
54.
PujosE., Cren-OlivéC., PaisseO.Comparison of the analysis of beta-blockers by different techniques.J Chromatogr B Analyt Technol Biomed Life Sci.2009 Dec 1; 877(31): 4007–14.
55.
SørensenL.K.A liquid chromatography-electrospray tandem mass spectrometry method for the determination of antiarrhythmic drugs and their metabolites in forensic whole blood samples.J Anal Toxicol.2012 Mar; 36(2): 116–22.
56.
LuchiR.J.Intoxication with quinidine.Chest.1978 Feb; 73(2): 129–31.
57.
RagostaM., WeihlA.C., RosenfieldL.E.Potentially fatal interaction between erythromycin and disopyramide.Am J Med.1989 Apr; 86(4): 465–6.
NygaardT.W., SellersT.D., CookT.S., DiMarcoJ.P.Adverse reactions to antiarrythmic drugs during therapy for ventricular arrhythmias.JAMA.1986 Jul 4; 256(1): 55–7.
60.
Hammett-StablerC.A., JohnsT.Laboratory guidelines for monitoring of antimicrobial drugs. National Academy of Clinical Biochemistry.Clin Chem.1998 May; 44(5): 1129–40.
61.
LiB., ZhangT., XuZ., FangH.H.Rapid analysis of 21 antibiotics of multiple classes in municipal wastewater using ultra performance liquid chromatography-tandem mass spectrometry.Anal Chim Acta.2009 Jul 10; 645(1-2): 64–72.
62.
WangJ.Analysis of macrolide antibiotics, using liquid chromatography-mass spectrometry, in food, biological and environmental matrices.Mass Spectrom Rev.2009 Jan-Feb; 28(1): 50–92.
63.
RayW.A., MurrayK.T., HallK.Azithromycin and the Risk of Cardiovascular Death.N Engl J Med.2012 May 17; 366(20): 1881–90.
64.
LiuP., LiangS., WangB.J., GuoR.C.Development and validation of a sensitive LC-MS method for the determination of promethazine hydrochloride in human plasma and urine.Eur J Drug Metab Pharmacokinet.2009 Jul-Sep; 34(3-4): 177–84.
65.
BorgesN.C., RezendeV.M., SantanaJ.M.Chlor-promazine quantification in human plasma by UPLC-electrospray ionization tandem mass spectrometry. Application to a comparative pharmacokinetic study.J Chromatogr B Analyt Technol Biomed Life Sci.2011 Dec 1; 879(31): 3728–34.
66.
ArinobuT., HattoriH., IwaiM.Liquid chromato-graphic-mass spectrometric determination of haloperidol and its metabolites in human plasma and urine.J Chromatogr B Analyt Technol Biomed Life Sci.2002 Aug 25; 776(1): 107–13.
67.
SaarE., GerostamoulosD., DrummerO.H., BeyerJ.Identification and quantification of 30 antipsychotics in blood using LC-MS/MS.J Mass Spectrom.2010 Aug; 45(8): 915–25.
68.
SaarE., BeyerJ., GerostamoulosD., DrummerO.H.The time-dependant post-mortem redistribution of antipsy-chotic drugs.Forensic Sci Int.2012 Jun 27. [Epub ahead of print].
69.
MartellB.A., ArnstenJ.H., KrantzM.J., GourevitchM.N.Impact of methadone treatment on cardiac repolarization and conduction in opioid users.Am J Cardiol.2005 Apr 1; 95(7): 915–8.
